THREAD and CureClick Partner in DCT Recruitment
THREAD and CureClick have announced a new partnership focused on engaging social media influencers to increase recruitment outcomes in decentralized clinical trials (DCTs). Combining THREAD’s platform with CureClick’s network of more than 100,000 patient activists and advocates, influencers can now highlight potentially life-saving DCTs within targeted social media networks to possibly achieve increased enrollment, retention, and satisfaction rates.
CureClick increases clinical trial awareness and accelerates patient recruitment by enabling trusted members of online communities to easily find and disseminate accurate, patient-friendly information across their social networks. Through this partnership, CureClick patient activists, or “ambassadors,” will deliver eligible participants to THREAD’s automated participant recruitment and onboarding solution.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
